Science is on the cusp of a radical transformation. Groundbreaking research at the University of California, San Francisco (UCSF) introduces an innovative method that reprograms T cells directly within the human body. This in vivo engineering approach bypasses ex vivo manufacturing entirely, potentially dismantling barriers that have long restricted access to these life-saving treatments. By utilizing a sophisticated dual-particle delivery system, scientists can now precisely insert new genetic instructions into T cells still circulating in the bloodstream, revolutionizing the speed, cost, and accessibility of immunotherapy.

The crux of this innovation lies in the ability to integrate large DNA sequences site-specifically into the genome of T cells without removing them from the body—a feat never before accomplished at such precision. Traditional CAR-T manufacturing involves viral vectors that randomly insert CAR genes into the genome, a process that can lead to unpredictable outcomes and requires rigorous quality controls. The UCSF team’s technique leverages CRISPR-Cas9 gene-editing technology to install the CAR gene at a molecular “on switch” locus unique to T cells. This precise insertion ensures robust, controlled expression of CAR molecules, thereby enhancing the therapeutic efficacy while minimizing off-target effects.

Central to this breakthrough is the design of a dual-particle system comprising two distinct nanoparticles. One particle is cloaked in antibodies targeting the CD3 protein, exclusively expressed on T cells, enabling selective delivery of gene-editing machinery to intended immune cells. The second particle encodes the new DNA sequence for the CAR, paired with the necessary homology arms to guide its integration into the specific genomic location. This ingenious partnership of particle design ensures that only T cells receive and incorporate the CAR gene, addressing safety concerns inherent in gene therapy.

Preclinical trials conducted in mice humanized with immune cells yielded astonishing results. A single intravenous injection of the dual-particle system led to the clearance of aggressive leukemias in nearly all treated subjects within two weeks. The engineered CAR-T cells proliferated extensively, constituting up to 40% of immune cells in various organs such as the bone marrow and spleen, demonstrating potent eradication of cancer in difficult-to-reach reservoirs. These outcomes alone signal a paradigm shift in immunotherapy delivery.

Moreover, the UCSF researchers extended their in vivo editing approach to combat multiple myeloma, another challenging hematologic malignancy, and—remarkably—to solid tumors such as sarcomas, which have historically resisted CAR-T assaults. The ability to target solid tumors represents a significant stride, broadening CAR-T applicability beyond hematologic cancers and into the realm of notoriously refractory malignancies.

Intriguingly, the T cells reprogrammed within the living organism exhibited superior functional qualities compared to those manufactured ex vivo. Cells engineered outside the body often lose “stemness,” a critical feature associated with sustained proliferation and longevity, due to ex vivo expansion and environmental stress. In contrast, in vivo engineered T cells retained a more natural state with enhanced proliferative potential, suggesting improved persistence and therapeutic durability once infused.

This research, though promising, demands further development before human clinical application. Scaling the dual-particle delivery system for use in patients and rigorously evaluating safety and efficacy through clinical trials remain essential next steps. To accelerate this translational journey, the leadership at UCSF has launched Azalea Therapeutics, a company dedicated to advancing this novel platform toward clinical reality and democratizing the availability of CAR-T therapy worldwide.

The implications of this breakthrough extend far beyond science labs and clinical trials. Presently, CAR-T treatments are confined to specialized cancer centers due to the complexities of manufacturing and administration. By enabling in vivo genetic editing, this technique holds the promise to bring cutting-edge immunotherapy to community hospitals and clinics globally. It could transform deadly cancers into manageable diseases for countless patients and dramatically reduce the financial burden associated with these therapies.

“In vivo manufacturing marks a seismic shift in the treatment landscape—potentially allowing for both rapid and affordable immune reprogramming inside the patient,” said Dr. Justin Eyquem, associate professor of medicine at UCSF and senior author of the study. “If successfully translated to clinical settings, this approach could save more lives and fundamentally alter how we think about cancer immunotherapy delivery.”

Beyond cancer, the implications for gene and cell therapy are vast. The precision, efficiency, and safety embodied in this site-specific in vivo gene editing platform open new frontiers to treat a myriad of diseases that hinge on cellular dysfunction or genetic defects. The fusion of nanoparticle targeting technology with CRISPR-mediated editing could become the prototype for next-generation medicines tackling autoimmune diseases, genetic disorders, and infectious diseases.

This landmark study, published in the journal Nature, heralds a new chapter in personalized medicine and immunotherapy. It challenges long-standing paradigms and offers hope to patients previously excluded from the benefits of CAR-T cell therapy due to logistical, financial, or physiological constraints. As researchers advance this technique toward human trials, the oncology community waits with hopeful anticipation for a future where gene-engineered immune cells can be summoned swiftly and safely from within, ushering a new era of cancer treatment.

Subject of Research: Animals
Article Title: In vivo site-specific engineering to reprogram T cells
News Publication Date: 18-Mar-2026
Web References: https://doi.org/10.1038/s41586-026-10235-x
References: Eyquem J, Nyberg W, Bernard P-L, et al. In vivo site-specific engineering to reprogram T cells. Nature. 2026; DOI: 10.1038/s41586-026-10235-x.
Image Credits: University of California, San Francisco

Keywords: Cancer immunotherapy, CAR-T cell therapy, in vivo gene editing, CRISPR-Cas9, nanoparticle delivery, T cell engineering, leukemia, multiple myeloma, solid tumors, gene therapy, immuno-oncology, translational medicine

Standard frontline therapies have improved survival rates; however, patients who experience relapse or are refractory to conventional treatments confront a grim prognosis. A breakthrough in recent years has been the introduction of immunotherapies targeting the CD19 antigen—a surface protein ubiquitously expressed on B-ALL cells. CAR-T (chimeric antigen receptor T-cell) therapies engineered to recognize CD19 have revolutionized treatment paradigms, demonstrating remarkable initial response rates. Yet, clinical outcomes remain unsatisfactory for a substantial subset of patients, with nearly half relapsing primarily due to cancer cells orchestrating immune evasion via downregulation or loss of CD19 expression.

Addressing this mechanism of immune escape, researchers from the Josep Carreras Leukaemia Research Institute and Hospital 12 de Octubre – CNIO undertook pioneering experimental work to develop a dual-targeted CAR-T cell therapy. Led by Dr. Pablo Menéndez, Dr. Clara Bueno, and Dr. Luis Álvarez Vallina, the team designed genetically modified T-cells capable of simultaneously targeting two distinct B-ALL surface antigens: CD19 and CD22. CD22 serves as an alternative, non-overlapping marker consistently present on leukemic blasts, presenting a rational target to complement CD19.

The innovation lies in the sophisticated engineering of the CAR-T cells to combine two complementary strategies within a single therapeutic agent. These CAR-T cells deploy a conventional chimeric antigen receptor construct directed against CD22, facilitating direct cytotoxic engagement of leukemic populations expressing this marker. Simultaneously, these engineered T-cells secrete a bispecific T-cell engager (BiTE) molecule focused on recruiting endogenous T-cells—irrespective of their CAR-T status—towards the CD19 antigen on the tumor cells. This dual mechanism effectively "double-dips" the immune response, enhancing both precision and breadth of leukemic cell targeting.

This approach leverages the unique strengths of both CAR-T technology and bispecific antibody therapy. CAR-T cells offer the advantage of long-lived persistence and sustained cytotoxicity, capable of trafficking throughout the body to eliminate malignancies. In contrast, bispecific antibodies function as bridges that physically tether cytotoxic T-cells to cancer cells, promoting potent immune synapse formation and rapid tumor cell lysis. By integrating BiTE secretion within CAR-T cells, the therapy amplifies immune activation and recruitment, mitigating the risk of tumor cells escaping immune surveillance through antigen loss variants.

Preclinical in vitro investigations revealed that these dual-targeting CAR-T cells markedly improved leukemic control compared to single-antigen targeting counterparts. The bispecific engagement significantly increased the recruitment and activation of bystander T-cells to CD19-expressing leukemia cells, while the direct CD22 CAR-mediated cytotoxicity ensured clearance of leukemic clones that had escaped CD19 targeting. Importantly, this led to prolonged control of leukemic growth and potential reduction in relapse incidence.

Published in the Journal for ImmunoTherapy of Cancer and co-authored by Javier Arroyo Ródenas and Aïda Falgàs, the study marks a pioneering step towards next-generation CAR-T immunotherapies that circumvent antigen escape mechanisms—one of the most formidable barriers to durable remission in relapsed B-ALL. The researchers emphasize that the bifunctional design could redefine treatment paradigms, offering renewed hope for pediatric patients facing limited options after relapse.

The success of this experimental study underscores the importance of multi-antigen targeting within immuno-oncology, particularly in hematological malignancies where antigen heterogeneity and plasticity fuel therapeutic resistance. By harnessing the endogenous immune system’s full cytotoxic potential and imparting long-term surveillance capacity, these "armored" CAR-T cells embody a strategic advance in precision medicine.

Furthermore, the modular construction of these CAR-T cells facilitates adaptability; the BiTE component secreted could theoretically be re-engineered to target alternative tumor-specific antigens or combined with additional immune-stimulatory molecules. This flexibility paves the way for bespoke immunotherapies tailored to diverse malignancies characterized by complex antigenic landscapes.

This research was made possible through funding by several esteemed institutions, including the European Commission’s ERC program, multiple Spanish governmental bodies, regional funds from the Generalitat de Catalunya and Comunidad de Madrid, as well as private entities dedicated to cancer research. Such robust support reflects the growing recognition that innovative immunotherapy solutions are crucial to addressing unmet clinical needs in childhood cancers.

As this CAR-T and bispecific antibody fusion approach progresses towards clinical translation, its implications extend beyond B-ALL. Similar dual-targeting strategies may be exploited for other refractory hematologic cancers and solid tumors notorious for evading mono-targeted immunotherapies. The future of cancer treatment undoubtedly lies in combinatorial immunotherapeutic designs that enhance efficacy while mitigating resistance.

Overall, this study presents a timely, technologically sophisticated immunotherapeutic platform with the potential to transform leukemia care. Its dual targeting mechanism heralds a paradigm shift toward more resilient, lasting remissions for children afflicted with one of the most prevalent and deadly pediatric cancers. Ongoing research and eventual clinical trials will determine its full impact on patient survival and quality of life worldwide.

Subject of Research: Cells

Article Title: CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

News Publication Date: 30-Apr-2025

Web References:
https://doi.org/10.1136/jitc-2024-009048

References:
Arroyo-Ródenas J, Falgàs A, Díez-Alonso L, et al. “CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression”. Journal for ImmunoTherapy of Cancer. 2025;13:e009048. doi:10.1136/jitc-2024-009048

Image Credits: Josep Carreras Leukaemia Research Institute

Keywords: Immunotherapy, Antibody therapy, Cancer immunotherapy, Antibodies, Leukemia

A stalwart in the realm of medical research, Dr. Mackall serves as the Ernest and Amelia Gallo Family Professor as well as a professor of pediatrics and medicine at Stanford University. Her leadership extends to the founding directorship of the Stanford Center for Cancer Cell Therapy, alongside her role as the director of the Parker Institute for Cancer Immunotherapy. Notably, Mackall’s research spans a decade of innovative studies aimed at deciphering the intricate mechanisms by which the immune system can be leveraged to fight malignancies, specifically highlighting her contributions to CAR T-cell therapies—a revolutionary advancement in personalized cancer treatment.

Mackall’s illustrious career is characterized by her insightful advancements in the understanding of T-cell homeostasis, particularly through her pivotal discovery of interleukin-7 (IL-7) roles. This cytokine plays a vital role in maintaining T-cell populations, and her work has laid the theoretical groundwork for various therapies that utilize this biological knowledge to enhance immune responses against cancer. Her path-breaking clinical trials have redefined treatment algorithms, especially for pediatric cancer patients, establishing her reputation as a leading figure in the field.

One of Mackall’s crowning achievements is her pioneering research surrounding chimeric antigen receptor (CAR) T-cells. As one of the first researchers to investigate CD19-targeted CAR T-cell therapy in pediatric patients suffering from B-cell acute lymphoblastic leukemia, her studies demonstrated remarkable response rates, positioning CAR T-cell therapy as a therapeutic mainstay in treating various hematological malignancies. However, Mackall is not one to rest on her laurels, as she continually investigates the underlying mechanisms of resistance that can diminish the effectiveness of these therapies.

A notable impact of Mackall’s work is her recent focus on extending the applicability of CAR T-cell therapies to solid tumors, which historically have posed a significant challenge for oncologists. Her ongoing research is poised to broaden the horizons of CAR T-cell therapy, aiming to transition its benefits from hematologic malignancies into the realm of solid tumors, thereby fulfilling a major unmet need in the field of cancer treatment. This ambitious endeavor reflects her commitment to improving outcomes for all cancer patients, particularly those who have fewer viable treatment options.

Dr. Mackall’s influence extends beyond her research portfolio; she has played an instrumental role in shaping the future of cancer immunotherapy through her dedicated involvement in various committees and working groups within the AACR. This includes membership and leadership roles in committees aimed at advancing pediatric oncology, education, and immunotherapy research initiatives. Her relentless dedication to fostering collaboration among scientists and clinicians ensures that the pursuit of innovative cancer therapies remains at the forefront of medical research.

The AACR-CRI Lloyd J. Old Award was initiated in 2013 with the goal of honoring outstanding cancer immunologists whose work has expanded our understanding of the immune response to cancer. Dr. Mackall’s selection as this year’s honoree underscores not only her individual achievements but also the evolving nature of cancer research as a collaborative and interdisciplinary endeavor. The award ceremony will take place during the AACR Annual Meeting, where Mackall will also deliver an award lecture detailing her groundbreaking findings and contributions to cancer research.

In light of her numerous accolades, including her recent election to the AACR Board of Directors, Dr. Mackall’s reputation is further solidified by an impressive list of awards recognizing her extraordinary contributions to the field of oncology. Her dedication has not gone unnoticed, earning her numerous recognitions from esteemed institutions and organizations within the medical and scientific communities. These awards are a testament to her relentless pursuit of excellence and her pioneering spirit, which continues to inspire both her peers and the next generation of cancer researchers.

Mackall’s influence resonates not only through her research and administrative roles but also in her commitment to mentoring young scientists. By fostering an environment of innovation and inquiry, she plays a crucial part in guiding emerging researchers in the field of oncology. Her mentorship is invaluable in shaping the future of cancer treatment as she encourages aspiring scientists to challenge the status quo and explore novel therapeutic approaches that could redefine patient care.

As the field of cancer research advances, the importance of collaboration and knowledge sharing becomes increasingly paramount. Dr. Mackall exemplifies this collaborative spirit through her participation in multi-institutional research initiatives, including her roles on various editorial boards and steering committees. Her involvement ensures that significant findings are disseminated widely, affording oncologists and researchers alike the opportunity to leverage shared information to enhance treatment options for cancer patients.

In addition to her scientific endeavors, Dr. Mackall often emphasizes the necessity of translating research findings into clinically actionable strategies. This crucial step bridges the gap between laboratory discoveries and patient care, ensuring that the latest innovations in cancer immunotherapy reach the individuals who need them most. Her commitment to translational research exemplifies a holistic approach to cancer treatment, where innovation is constantly infused into clinical practice.

With the AACR-CRI Lloyd J. Old Award in hand and an ever-expanding legacy, Crystal L. Mackall stands at the forefront of cancer immunology, a leader whose research continues to break barriers and transform the lives of countless patients. As she prepares to share her insights at the upcoming annual meeting, the scientific community eagerly anticipates the next chapter of her groundbreaking work. Her contributions will not only influence the immediate landscape of cancer research but also shape the future trajectory of treatment paradigms for years to come.

As we navigate the complex world of cancer treatment, the importance of visionary leaders like Dr. Mackall cannot be overstated. Her influence, expertise, and dedication serve as a guiding light for current and future generations of researchers, clinicians, and patients alike. The journey of cancer immunotherapy is ongoing, and with pioneers like Mackall leading the way, the horizons of hope continue to expand for patients combating this formidable disease.

Subject of Research: Cancer Immunotherapy and CAR T-cell Therapy
Article Title: Crystal L. Mackall Honored with Prestigious Cancer Immunology Award
News Publication Date: [Insert Date]
Web References: [Insert relevant URLs if applicable]
References: [Insert relevant citations if applicable]
Image Credits: [Insert if applicable]

Keywords: Cancer Immunology, CAR T-cell Therapy, Cancer Research, Pediatric Oncology, Translational Research, T-cell Homeostasis, Immune Response, Clinical Trials, Cancer Treatment, AACR-CRI Award

The clinical trial investigating the TCR therapy known as letetresgene autoleucel (lete-cel) has shown remarkable promise for patients suffering from advanced myxoid/round cell liposarcoma, a rare and typically aggressive form of soft tissue cancer. This trial represents a pioneering effort, drawing the attention of researchers and oncologists alike, as it sets a precedent in the applicability of engineered T cell therapies for rare tumor types that often elude conventional treatment modalities. Notably, the trial revealed that among patients receiving higher doses of chemotherapy followed by lete-cel, there was a remarkable 40% response rate.

The implications of these results are manifold, particularly as they underscore the significance of tailoring treatment regimens to enhance therapeutic efficacy. With a demographic that often sees few options due to the overbearing nature of relapsing cancer, the demonstrated efficacy of lete-cel, especially for those who fail to respond to existing therapies, signals a potential turning point in the clinical management of myxoid/round cell liposarcoma.

Letetresgene autoleucel employs a sophisticated mechanism of action that involves engineering the patient’s T cells with receptors specifically designed to target the NY-ESO-1 antigen, a protein commonly present in these tumors. This particular strategy adeptly leverages the body’s immune response, offering a potent retort against malignant cells that would otherwise elude standard therapies. The leadership of Dr. Sandra D’Angelo, a noted sarcoma expert, marks a significant milestone in cancer immunotherapy, inspiring further investigations that can refine and redefine treatment protocols.

Further illustrating the potential of CAR T cell therapy, a separate study led by Dr. Jae Park revealed encouraging results for patients diagnosed with large B cell lymphoma. The modification made in this realm involved the genetic engineering of CAR T cells—specifically, the inclusion of a molecule known as 1XX. This modification proves pivotal as it mitigates the phenomenon of T cell exhaustion, a common limitation faced in conventional CAR T therapies where T cells lose their efficacy over time. Through this creative innovation, the researchers attained an overall response rate of an astounding 82% among the trial participants, indicating that such engineered T cells can maintain their therapeutic potency.

The clinical ramifications extend beyond response rates alone; they also hint at the possibility of reduced doses in administering T cell therapies. Such developments not only suggest a more refined approach to treatment that may lower the intensity of side effects but also aligns with a broader trend towards precision medicine, where individual patient responses are prioritized and optimized.

In tandem with these advancements in cell therapies, significant strides are being made in the field of nanoparticle drug delivery systems. The research conducted under the guidance of Dr. Daniel Heller at MSK explores the encapsulation of therapeutic agents within nanoparticles to enhance their efficiency while minimizing systemic exposure. This endeavor is crucial, as traditional drug delivery methods often result in adverse effects due to unspecific targeting of both cancerous and healthy tissues alike. By developing peptide-based nanoparticles capable of achieving over 98% drug loading, this research proposes a paradigm shift in how therapeutics can be more effectively delivered to malignancies while preserving normal tissue integrity.

The implications of enhanced drug-loading efficiency are profound, particularly for drug candidates that have been deemed ineffective or too toxic for clinical use in their conventional formulations. Moreover, the data generated from mouse models of acute myeloid leukemia reinforce the potential of these peptide-encapsulated nanoparticles to deliver substantial anti-tumor effects. This research beckons a future where advancements in material sciences converge with clinical oncology, presenting synergistic opportunities to refine cancer drug efficacy and patient safety.

Moreover, researchers at MSK have turned their attention to novel methodologies that involve engineering CAR T cells capable of specifically activating within tumor microenvironments. By designing T cells that bind to P-selectin, a protein prevalent in newly formed blood vessels around tumors, the potential treatment can focus its cytotoxic effects precisely where they are needed while sparing healthy tissues from collateral damage. The successful infiltration of MEAT (tumor microenvironment-activated) T cells during mouse studies provides optimism for broad applications across solid tumor types, positing a significant evolution in the therapeutic landscape of cancer care.

Interestingly, while advancements are promising, they do not come without challenges. Researchers have noted that in rare instances, CAR T cell treatments may inadvertently result in the emergence of new malignancies. Investigating such occurrences provides vital insights into the complex mechanisms underlying immune responses. Dr. Sham Mailankody and his team have identified instances where viral vectors used in gene therapies integrated into essential tumor suppressor genes, potentially disrupting their protective functions. Through meticulous research into the case of a patient who developed lymphoma post-CAR T treatment, the team highlights the necessity of continued vigilance and understanding of the multifaceted interactions between engineered therapies and host biology.

Real-world applications of these findings extend beyond laboratory settings; they push the boundaries on how oncologists can approach treatment not merely as a reactive measure but as a proactive engagement with the immune system’s intricacies. The collaboration among experts investigating the emerging side effects reaffirms the commitment to patient safety while generating knowledge that can refine protocols and inform clinical guidelines.

As this tapestry of research unfolds, it becomes increasingly evident that we are on the cusp of a new era in cancer treatment—one that champions innovation, patient-tailored therapies, and an informed understanding of the evolving interplay between cancer and immune responses. The future holds promise, yet it is through diligence, research, and a collective dedication to improving patient outcomes that we can navigate the complexities of cancer treatment with success.

These developments at Memorial Sloan Kettering Cancer Center herald not merely isolated triumphs in clinical trials but rather signify a monumental collective effort in redefining cancer therapeutics. As researchers continue to explore and refine these innovative treatments, the balance of efficacy and safety remains central to the advancements in cancer care and will undoubtedly shape the landscape for years to come.

Subject of Research: Advancements in Cancer Immunotherapy
Article Title: Novel Approaches in Targeting Rare Cancers: The Future of CAR T Therapy and Nanoparticle Drug Delivery
News Publication Date: October 2023
Web References: None available
References: None available
Image Credits: Memorial Sloan Kettering Cancer Center
Keywords: Cancer research, Cell therapies, Immunotherapy, Nanoparticles, CAR T therapy, Clinical trials